Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany

European Journal of Health Economics

Volumn 6, Issue 4, 2005, Pages 317-321

  Kulp, Werner ^a,b   Graf Von Der Schulenburg, J M ^a   Greiner, Wolfgang ^b  

^a BIELEFELD UNIVERSITY   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

Cost effectiveness; Depression; Escitalopram; Germany; Venlafaxine

Indexed keywords

AMITRIPTYLINE; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; VENLAFAXINE; VILOXAZINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG INDICATION; DRUG RESPONSE; GERMANY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MEDICAL DECISION MAKING; MENTAL PATIENT; OUTPATIENT; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AMBULATORY CARE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG COSTS; DRUG UTILIZATION; GERMANY; HEALTH CARE SURVEYS; HUMANS; MARKOV CHAINS; MODELS, ECONOMETRIC; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 28944433603     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-005-0306-1     Document Type: Article

References (21)

1. Andersson IM, Nutt DJ, Deakin JFM (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psycholpharmacol 14:3-20
2. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, edn 4. American Psychiatric Association: Washington
3. Angst J, Gamma A, Gastpar M, Lépine JP, Mendlewicz J, Tylee A (2002) Gender differences in depression: epidemiological findings from the European DEPRES I, II studies. Eur Arch Psychiatry Clin Neurosci 252:201-209
4. Arzneimittelkommission der deutschen Ärzteschaft (1997) Empfehlungen Therapie Depression. Arzneimittelkommission der deutschen Ärzteschaft
5. Bielski RJ, Ventura D, Chang C-C (2004) A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychol 65:1190-1196
6. Burke WJ, Kratochvil J (2002) Stereoisomers in psychiatry: the case of escitalopram. Prim Care Comp J Clin Psychiatry 4:20-24
7. Croom KF, Plosker GL (2003). Escitalopram - a pharmacoeconomic review of its use in depression. Pharmacoeconomics 21:1185-1209
8. Deutsches Institut für Medizinische Information und Dokumentation (2004) ATC/DDD-GM Richtlinien (Version 2004).http://www.dimdi.de/dynamic/de/ klassi/download/atc1/index.html (accessed 28 September 2004)
9. Entsuah R, Huang H, Willard LB (2002) Venlafaxine and SSRIs: pooled remission analysis (mega-analysis of 31 studies of >7000 patients). Poster presented at the 18th World Congress of Psychotherapy, Trondheim, 14-18 August
10. Fritze J (2004) Psychopharmaka-Verordnungen: Ergebnisse und Kommentare zum Arzneiverordnungsreport 2003. Psychoneuroendocrinology 30:280-284
11. Fritze J, Saß H, Schmauß M (2001) Befragung der Fachgesellschaften durch den Sachverständigenrat für die Konzertierte Aktion im Gesundheitswesen zur Frage von Über-, Unter- und Fehlversorgung: Stellungnahme der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde(DGPPN).http://www.dgppn.de
12. Jacobi F, Höfler M, Meister W, Wittchen HU (2002) Prävalenz, Erkennens- und Verschreibungsverhalten bei depressiven Syndromen: eine bundesdeutsche Hausarztstudie. Nervenarzt 73:651-658
13. Maier W (2004) Genetik der Depression. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 47:487-492
14. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389
15. Montgomery SA, Huuson AK, Bothmer J (2004) A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 50:57-64
16. Sachverständigenrat für die konzertierte Aktion im Gesundheitswesen (2001) Gutachten Bedarfsgerechtigkeit und Wirtschaftlichkeit, vol III
17. Schulenburg JM von der, Mittendorf, T, Volmer, T et al (2005) The health economics handbook. Adis International: Munich
18. Statistisches Bundesamt (1998) Gesundheitsbericht für Deutschland. Statistisches Bundesamt: Wiesbaden
19. Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241
20. WHO (2001) The world health report 2001: mental health: new understanding, new hope. WHO
21. WHO (2004) ICD-10. The international statistical classification of diseases and related health problems, tenth revision.http://www.who.int/whosis/ icd10/ (accessed 28 September 2004)